Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier:
NCT00300118
First received: March 7, 2006
Last updated: May 16, 2014
Last verified: May 2014

March 7, 2006
May 16, 2014
September 2004
May 2008   (final data collection date for primary outcome measure)
Rate of remission
Same as current
Complete list of historical versions of study NCT00300118 on ClinicalTrials.gov Archive Site
  • Response to treatment
  • Time to response
  • Time to remission
  • PGA
  • QoL
  • Response to treatment
  • Time to response
  • Time to remission
  • PGA
  • SIBDQ
Not Provided
Not Provided
 
Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)
Double-blind, Double-dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients

The purpose of this study is to determine whether mesalazine or budesonide is more active in the treatment of active Crohn's disease.

Crohn's disease is often treated with glucocorticoids or mesalazine. Both drugs are indicated for active Crohn's disease. Treatment with mesalazine is indicated for the treatment of mildly to moderately active Crohn's disease. Budesonide 9 mg/day or mesalazine 4.5 g/day are better than lower doses.

So far only one trial compares the efficacy and safety of budesonide and 5-ASA. The result of this trial is that budesonide is more effective in inducing remission than mesalazine. The primary objective of this trial is to confirm this result for other presentations of budesonide and mesalazine; i.e. Budenofalk® capsules (9 mg/day) and Salofalk® tablets (Eudragit-L-coated oral mesalazine; 4.5 g/day) in moderately active Crohn's disease. Mesalazine is used in this trial as a comparator.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Crohn's Disease
  • Drug: budesonide
    9 mg
  • Drug: mesalazine
    4.5 g
  • Experimental: A
    Intervention: Drug: budesonide
  • Active Comparator: B
    Intervention: Drug: mesalazine
Tromm A, Bunganič I, Tomsová E, Tulassay Z, Lukáš M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R; International Budenofalk Study Group. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology. 2011 Feb;140(2):425-434.e1; quiz e13-4. doi: 10.1053/j.gastro.2010.11.004. Epub 2010 Nov 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
311
May 2008
May 2008   (final data collection date for primary outcome measure)

Inclusion Criteria (main):

  • Symptoms of Crohn's disease since at least 3 months; diagnosis confirmed by endoscopic and histological, or endoscopic and radiological criteria [endoscopy not older than 12 months or if older, then clinical signs (e.g. pain localization, pain intensity, blood in stool) and behaviour (according to Vienna classification) should be unchanged compared to former episodes]
  • Localisation of CD either in terminal ileum, ascending colon or ileocolitis
  • Active phase of disease (200 < CDAI < 400)

Exclusion Criteria (main):

  • Known Crohn's lesion in the upper GI-tract (up to and including the jejunum) with present symptoms
  • CD in the rectum currently present
  • Short bowel syndrome
  • Septic complications
  • Baseline stool positive for germs causing bowel disease
  • Abscess, perforation or active fistulas
  • Ileostomy or colostomy
  • Resection of more than 50 cm of the ileum
  • Bowel surgery within the last 3 months
  • Immediate surgery required
  • Clinical signs of stricturing disease
  • Subileus within the last 6 months
  • Suspicion of ileus, subileus or corresponding symptomatology
  • Contra-indications, special warnings and precautions mentioned in SmPC
  • Treatment with immunosuppressants, cytostatics, 6-TG, methotrexate, or cyclosporine within the last 3 months; in case of treatment with azathioprine or 6-MP the drugs have to be used for maintenance of remission only and dosage has to be unchanged within the last 3 months before baseline visit and during the study
  • Treatment with ketoconazole, ciprofloxacin or other CYP3A inhibitors within the last month before baseline visit
  • Treatment with anti-TNF-a therapy within 6 months before baseline visit
  • Conventional steroids (iv, po, rectal) within 2 weeks before the study
  • > 6 mg/d budesonide po or > 3 g/d mesalazine po within 2 weeks before the study
  • Patients known to be steroid-refractory or steroid-dependent from former CD episodes
  • Treatment of study disease with oral antibiotics (e.g., metronidazole) within the last 2 weeks
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00300118
BUC-52/CDA, 2004-001213-34
Yes
Dr. Falk Pharma GmbH
Dr. Falk Pharma GmbH
Not Provided
Principal Investigator: Andreas Tromm, Professor Ev. Krankenhaus Hattingen GmbH
Dr. Falk Pharma GmbH
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP